d(GC) - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and Pharmacy Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online) 62. NCBI-GeneTests. Dihydropyrimidine Dehydrogenase Deficiency. http:// www.ncbi.nlm.nih.gov/sites/GeneTests/lab/ clinical_disease_id/234208?db=genetests Accessed 31, Jan 2012 63. Wheeler, D., Dunn, E. and Harari, P. (2010). Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat Rev Clin Oncol, 7: 493-507. 64. Prenen, H., Tejpar, S., and Van Cutsem, E. (2010). New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res, 16: 2921-2926. 65. US-FDA. DakoCytomation EGFR 66. pharmDx(TM) - P030044. http:// www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm081222.htm Accessed 31, Jan 2012 Chung, K.Y., Shia, J., Kemeny, N.E., Shah, M., Schwartz, G.K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., Klimstra, D.S., Fridman, D., Kelsen, D.P., and Saltz, L.B. (2005). Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 23: 1803-10. 67. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O’Callaghan, C.J., Tu, D., Tebbutt, N.C., Simes, R.J., Chalchal, H., Shapiro, J.D., Robitaille, S., Price, T.J., Shepherd, L., Au, H.J., Langer, C., Moore, M.J., and Zalcberg, J.R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 359: 1757-65. 68. Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S.D. and Chang, D.D. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with Rebecca E. Smith and Juan Miguel Pascale 140 69. metastatic colorectal cancer. J Clin Oncol, 26: 1626-34. Eng, C. (2010). The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist, 15: 73-84. 70. Allegra, C.J., Jessup, J.M., Somerfield, M.R., Hamilton, S.R., Hammond, E.H., Hayes, D.F., McAllister, P.K., Morton, R.F., and Schilsky, R.L. (2009). American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor 71. monoclonal antibody therapy. J Clin Oncol, 27: 2091-6. Saridaki, Z., Georgoulias, V., and Souglakos, J. (2010). Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol, 16: 1177- 1187. 72. US-FDA. cobas® 4800 BRAF V600 Mutation Test - P110020. http:// www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm268836.htm Accessed 31, Jan 2012 73. Olopade, O.I., Grushko, T.A., Nanda, R., and Huo, D. (2008). Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res, 14: 7988-99. 74. Pruthi, S., Gostout, B.S., and Lindor, N.M. (2010). Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc, 85: 1111-1120. 75. Hopper, J.L., Chenevix-Trench, G., Jolley, D.J., Dite, G.S., Jenkins, M.A., Venter, D.J., McCredie, M.R., and Giles, G.G. (1999). Design and analysis issues in a populationbased, case-control-family study of the
Current Trends in Biotechnology and Pharmacy Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online) 76. genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr, 95-100. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian.; http://www.nccn.org/ professionals/physician_gls/ f_guidelines.asp#site Accessed 31, Aug 2011 77. Leung, M., Rosen, D., Fields, S., Cesano, A. and Budman, D.R. (2011). Poly(ADPribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med, 17: 854-62. 78. Mackay, J. and Szecsei, C.M. (2011). Genetic counselling for hereditary predisposition to ovarian and breast cancer. Ann Oncol, 21 Suppl 7: vii334-8. 79. Galvao, E.R., Martins, L.M., Ibiapina, J.O., Andrade, H.M. and Monte, S.J. (2011). Breast cancer proteomics: a review for clinicians. J Cancer Res Clin Oncol, 137: 915-25. 80. Miettinen, M. and Lasota, J. (2001). Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 438: 1-12. 81. Kim, K.M., Kang, D.W., Moon, W.S., Park, J.B., Park, C.K., Sohn, J.H., Jeong, J.S., Cho, M.Y., Jin, S.Y., Choi, J.S. and Kang, D.Y. (2005). Gastrointestinal stromal tumors in Koreans: its incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci, 20: 977-84. 82. Tryggvason, G., Gislason, H.G., Magnusson, M.K. and Jonasson, J.G. (2005). Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and Developing world personalized cancer medicine 141 pathologic risk stratification study. Int J Cancer, 117: 289-93. 83. Goettsch, W.G., Bos, S.D., Breekveldt- Postma, N., Casparie, M., Herings, R.M., and Hogendoorn, P.C. (2005). Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer, 41: 2868-72. 84. Downs-Kelly, E. and Rubin, B.P. (2011). Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Pathology Research International, 2011: 708596. 85. Yarden, Y., Escobedo, J.A., Kuang, W.J., Yang-Feng, T.L., Daniel, T.O., Tremble, P.M., Chen, E.Y., Ando, M.E., Harkins, R.N., Francke, U., Fried, V.A., Ullrich, A., and Williams, L.T. (1986). Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature, 323: 226- 32. 86. Yarden, Y., Kuang, W.J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T.J., Chen, E., Schlessinger, J., Francke, U., and Ullrich, A. (1987). Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J, 6: 3341-51. 87. Roskoski, R., Jr. (2005). Structure and regulation of Kit protein-tyrosine kinase— the stem cell factor receptor. Biochem Biophys Res Commun, 338: 1307-15. 88. Ikeda, H., Kanakura, Y., Tamaki, T., Kuriu, A., Kitayama, H., Ishikawa, J., Kanayama, Y., Yonezawa, T., Tarui, S. and Griffin, J.D. (1991). Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood, 78: 2962-8. 89. Nagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tannenbaum, S., Suzuki, Y., and Metcalfe, D.D. (1995). Identification of a point mutation in the catalytic domain
Page 3 and 4: Current Trends in Biotechnology and
Page 27: Current Trends in Biotechnology and
Page 79 and 80:
Current Trends in Biotechnology and
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
6th Annual Convention of Associatio
show all

d(GC) - Association of Biotechnology and Pharmacy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?